Generic threat: if you can’t beat them, buy them

The offer period is underway for Japanese pharma giant Daiichi Sankyo’s bid for Ranbaxy lab. Daiichi plans to acquire 20% of the firm in the open market, with private deals making up the rest of its eventual majority stake. The offer forms part of a trend in which established drugs firms deal with the threat of developing-world generics firms by buying, or copying, them. Another approach is to launch authorized generic to affect the sale of generic competitor.

Complete article Here
Earlier article of IPPharmadoc on his issue Here